Healthcare technology companies DoseSpot and Arrive Health have merged to combine an electronic prescribing platform with medical and pharmacy benefit data to improve real-time drug price transparency for providers and patients.
The companies say the new company, called Interra Health, will combine Arrive Health’s coverage and pricing network with DoseSpot’s e-prescribing capabilities to support prescribing decisions and help patients get the right medications at the lowest cost.
Bain Capital Technology Opportunities supports the transaction and will become majority owner. PSG, a former majority shareholder of DoseSpot, will become a minority shareholder. Other minority investors include Providence and UPMC Enterprises.
The combined company is profitable and growing at about 40% annually, with sales expected to exceed $100 million in 2026, executives said.
Josh Weiner, former CEO of DoseSpot, will serve as CEO and director of the newly combined company, and Kyle Kiser, former CEO of Arrive Health, will serve as a board member and senior advisor.
Arriv Health provides a network that provides real-time coverage and affordability insights from payers and pharmacies to the point of care. DoseSpot, on the other hand, offers prescribing and engagement tools that integrate directly into electronic health records, digital health and telemedicine platforms. The company says 50 million prescriptions are sent through DoseSpot each year.
With integrated technology, Interra Health will bring together coverage, prescribing, price transparency and access insights to support faster and better-informed treatment decisions, improve medication access and adherence, and reduce administrative burden, executives said. Interra Health serves 800,000 healthcare providers, and its infrastructure is purpose-built to serve artificial intelligence-native healthcare companies, executives said.
DoseSpot and Arrive Health have been partnering for several years, and the two companies were in the process of raising capital in 2025, Weiner told Fierce Healthcare in an exclusive interview about the merger.
“We saw an opportunity to build a broad platform to prescribe access and affordability. Bain Capital was the partner that really proposed that theory and vision that Kyle and I completely agreed with. And it was really clear to us that one plus one equals three,” Weiner said. “Arrive Health had built a network of approximately 700,000 providers; DoseSpot now serves 100,000 prescribers, and the opportunity to combine the breadth of the Arrive network with the depth of the DoseSpot solution was an opportunity that we were really excited about.”
Arriv Health provides real-time medical and pharmacy benefits information and integrates with EHR and electronic prescribing vendors. “The goal is to make the most affordable and most accessible decisions, thereby preventing administrative waste downstream, preventing prescription abandonment, and all of the confusion and complexity that often exists in today’s prescription value chain,” Kaiser said.
He added, “We also offer electronic prior authorization connectivity, leveraging EMR connectivity and connectivity to the payer and pharmacy benefit manager community to Or we can resolve prior authorizations when they’re done by the medical team. And we’re also starting to expand our capabilities more broadly with the medical team, so when a patient is seeking access to a medication, whether it’s with the pharmacy or with other medical team members, we’re also providing data solutions that expedite and enable that.” process. ”
The combined capabilities of DoseSpot and Arrive Health address existing friction points in the prescription experience. Healthcare providers and patients typically do not know what a drug will actually cost or whether it will be covered by insurance until the prescription leaves the doctor’s office. Coverage limitations, prior authorization requirements, and high out-of-pocket costs only surface after the prescription is submitted. This disconnect contributes to prior authorization delays, abandoned prescriptions, and billions in avoidable friction.
Interra Health’s integrated services give providers access to real-time coverage, costs, and point-of-care insights, while patients see clear coverage, affordability, and availability information. PBMs and payers can access benefit information in workflows to optimize prescribing decisions and improve the member experience. Pharmaceutical companies can more effectively connect patients to treatment by aligning coverage, affordability and support early in the process, executives said.
The combination will make the two companies’ capabilities bidirectional, Weiner said.
“Arrive Health brings real-time price transparency across all prescription events, allowing you to deepen your experience with the prescription workflows offered by DoseSpot and vice versa. “By bringing the capabilities that DoseSpot has been working on across our extensive EMR and PBM network into that environment, we can give patients more power and choice in how they review and process each prescription.” “We bring true price transparency, allowing patients to see what they will pay at the pharmacy when they are prescribed a drug and evaluate their options with their healthcare provider on the spot.”
According to data from Interra Health, approximately one-third of patients who browse pharmacy options choose to transfer their prescription after considering the available options.
The merger comes amid renewed focus on drug price transparency and PBM reform, as patients face rising drug costs.
“In a world where consumers and families are feeling tremendous pressure from the inflation that has occurred in recent years, drug affordability and price transparency around it is in the spotlight more than ever, and that’s driving so many partnership conversations and opportunities forward,” Weiner said.
There is a continuing shift within the health insurance industry toward increasing patient responsibility for prescription drug costs, but patients need better decision-making tools, Kaiser noted.
“What the future looks like to better serve patients is a consumer choice at the point of care and throughout the patient experience, which requires meaningful changes in how prescribing decisions are made and how we communicate with patients during that process,” he said. “When you lead a network business, you often rely heavily on many other partners to set the pace of innovation. What I’m most excited about is that this combination, by combining the Arrive network and DoseSpot’s suite of solutions to really set our own pace for that kind of change, puts the pace of innovation within our control and prepares us to meet patient needs as the market changes.”
The company plans to make significant investments in innovation, backed by Bain Capital. “What we’ll be doing over the next few quarters, and what we’re going to do as we’re coming together as an organization, is identify which friction points in the prescription process are a good fit for our unique reductions and work with all of our technology partners to resolve them,” Weiner said.
“We are proud to be chosen as a partner of choice by DoseSpot and Arrive Health. The combined business is uniquely positioned to address the most critical pain points in the prescribing process for patients, prescribers, pharmacies, and pharmaceutical companies,” Michael Grandfield, partner at Bain Capital Tech Opportunities, said in a statement.
“We look forward to leveraging our business-building capabilities and deep domain expertise to support Inra Health’s future growth,” said Todd Markson, partner at Bain Capital Tech Opportunities.
